Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy.

Conticello C, Del Fabro V, Romano A, Mele A, Mina R, Bringhen S, Orofino A, Antonioli E, Pulini S, De Paoli L, Za T, Cotzia E, Elia F, Casson A, Prete E, Citiso S, Liberatore C, Margiotta-Casaluci G, Fazio F, Morè S, Attucci I, Accardi F, Bongarzoni V, Mangiacavalli S, Rossi E, Mannina D, Garibaldi B, Rizzi R, Di Cecca M, Rossini B, Uccello G, Botta C, Leotta D, Vincelli D, Gentile M, Piciocchi A, Marsili G, Patriarca F, Zambello R, Musto P, Boccadoro M, Offidani M, Petrucci MT, Di Raimondo F

Open source

DOI
10.1007/s00277-025-06602-9
Published
2025 Oct
Container
Annals of hematology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s00277-025-06602-9,
  title = {Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy.},
  author = {Conticello C and Del Fabro V and Romano A and Mele A and Mina R and Bringhen S and Orofino A and Antonioli E and Pulini S and De Paoli L and Za T and Cotzia E and Elia F and Casson A and Prete E and Citiso S and Liberatore C and Margiotta-Casaluci G and Fazio F and Morè S and Attucci I and Accardi F and Bongarzoni V and Mangiacavalli S and Rossi E and Mannina D and Garibaldi B and Rizzi R and Di Cecca M and Rossini B and Uccello G and Botta C and Leotta D and Vincelli D and Gentile M and Piciocchi A and Marsili G and Patriarca F and Zambello R and Musto P and Boccadoro M and Offidani M and Petrucci MT and Di Raimondo F},
  year = {2025},
  journal = {Annals of hematology},
  doi = {10.1007/s00277-025-06602-9},
  url = {https://doi.org/10.1007/s00277-025-06602-9}
}

RIS

TY  - JOUR
TI  - Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy.
AU  - Conticello C
AU  - Del Fabro V
AU  - Romano A
AU  - Mele A
AU  - Mina R
AU  - Bringhen S
AU  - Orofino A
AU  - Antonioli E
AU  - Pulini S
AU  - De Paoli L
AU  - Za T
AU  - Cotzia E
AU  - Elia F
AU  - Casson A
AU  - Prete E
AU  - Citiso S
AU  - Liberatore C
AU  - Margiotta-Casaluci G
AU  - Fazio F
AU  - Morè S
AU  - Attucci I
AU  - Accardi F
AU  - Bongarzoni V
AU  - Mangiacavalli S
AU  - Rossi E
AU  - Mannina D
AU  - Garibaldi B
AU  - Rizzi R
AU  - Di Cecca M
AU  - Rossini B
AU  - Uccello G
AU  - Botta C
AU  - Leotta D
AU  - Vincelli D
AU  - Gentile M
AU  - Piciocchi A
AU  - Marsili G
AU  - Patriarca F
AU  - Zambello R
AU  - Musto P
AU  - Boccadoro M
AU  - Offidani M
AU  - Petrucci MT
AU  - Di Raimondo F
PY  - 2025
JO  - Annals of hematology
DO  - 10.1007/s00277-025-06602-9
UR  - https://doi.org/10.1007/s00277-025-06602-9
ER  -

APA

C, C., V, D. F., A, R., A, M., R, M., S, B., A, O., E, A., S, P., L, D. P., T, Z., E, C., F, E., A, C., E, P., S, C., C, L., G, M., F, F., S, M., I, A., F, A., V, B., S, M., E, R., D, M., B, G., R, R., M, D. C., B, R., G, U., C, B., D, L., D, V., M, G., A, P., G, M., F, P., R, Z., P, M., M, B., M, O., MT, P., & F, D. R. (2025). Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy.. Annals of hematology. https://doi.org/10.1007/s00277-025-06602-9

Source records